UMN Pharma
UMN Pharma is dedicated to developing a new generation of gentle vaccines using cutting-edge biotechnologies, aiming to make vaccines safe for babies, pregnant women, and the elderly. Their mission is to deliver these gentle vaccines quickly and to as many people as possible.
Industries
biotechnology
manufacturing
medical
pharmaceutical
Nr. of Employees
small (1-50)
Products
Recombinant protein vaccine candidates (in development)
Next-generation vaccine candidates developed with biotechnology methods and formulated for safety across infants, pregnant women, and elderly populations.
Recombinant protein vaccine candidates (in development)
Next-generation vaccine candidates developed with biotechnology methods and formulated for safety across infants, pregnant women, and elderly populations.
Services
Vaccine manufacturing and process development services
On-site services covering initial process development for recombinant protein vaccines, manufacture of clinical trial materials, and scale-up to commercial production.
Vaccine manufacturing and process development services
On-site services covering initial process development for recombinant protein vaccines, manufacture of clinical trial materials, and scale-up to commercial production.
Expertise Areas
- Vaccine research and development
- Recombinant protein vaccine development
- CMC and process scale-up
- Clinical supply manufacturing
Key Technologies
- Recombinant protein expression and purification
- Vaccine platform technologies
- Process development and scale-up methodologies
- Clinical trial material manufacturing